ArticleFrontiers in oncology2026
Systems toxicology unravels multi-tiered carcinogenic networks of zearalenone in gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer (GC) is a leading cause of cancer mortality worldwide, and dietary factors like mycotoxins play a significant role in its etiology. Zearalenone (ZEN), a widespread grain contaminant, is a suspected carcinogen; however, its molecular mechanisms in GC remain unclear. This study used an integrated systems toxicology approach to identify key targets and pathways of ZEN-induced GC and validate the findings. Methods: An integrated computational and experimental strategy was used. GC-related genes were identified from Gene Expression Omnibus (GEO) datasets using differential expression and weighted gene co-expression network analysis (WGCNA). ZEN targets were obtained from multiple databases. Common targets were analyzed for pathway enrichment and protein-protein interactions. Eleven machine learning algorithms screened for core driver genes among these common targets. The binding stability of ZEN to core targets was assessed using molecular docking and 100-ns molecular dynamics simulations. In vitro functional validation was performed using CCK-8, colony formation, EdU, and wound healing assays on the human GC cell line MKN-45. Results: We identified 157 common targets of ZEN and GC. Enrichment analysis highlighted key pathways, including P13K-Akt signaling and glycolysis. Machine learning identified six core driver genes (COL1A1, INHBA, PKM2, THBS2, MFAP2, and CPA2) with high diagnostic potential (AUC>0.85). Molecular simulations confirmed ZEN forms stable complexes with core targets, particularly PKM2 and THBS2. In vitro experiments showed low concentrations of ZEN (40-80 nM) significantly promoted proliferation and migration of MKN-45 cells, demonstrating a hormetic effect. Discussion: This study suggests ZEN promotes GC progression through a multi-level network. ZEN may directly modulate key effector proteins such as PKM2 to induce metabolic reprogramming. The observed hormetic pro-proliferative and pro-migratory responses were linked to the pre-existing activation state of the PI3K/Akt pathway. These findings provide novel mechanistic insights into the carcinogenic risk of ZEN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.